Anabolic effects of insulin and IGF-I in the ovine fetus are reduced by prolonged maternal fasting.
Fetal nutritional stress may result in intrauterine growth restriction and postnatal insulin resistance. To determine whether insulin resistance can begin in utero, we subjected late-gestation (130-135 days) ewes to 120 h of complete fasting and compared the results with our previous work in fed ewes (38). We determined the effect of insulin and/or recombinant human (rh)IGF-I infusion on ovine fetal phenylalanine kinetics, protein synthesis, and phenylalanine accretion. Experimental infusates were 1) saline, 2) rhIGF-I plus a replacement dose of insulin (40 nmol IGF-I/h + 16 mIU insulin/h), 3) insulin (890 mIU/h), and 4) IGF-I plus insulin (40 nmol IGF-I/h + 890 mIU insulin/h). During hormone infusion, both glucose and amino acid concentrations were clamped at basal concentrations. Amino acid infusion was required during infusion of either hormone to maintain plasma concentrations constant. However, the amount required during insulin infusion was less than during IGF-I infusion and 40% less than the amount required during identical studies in nonfasted animals. Phenylalanine used for protein synthesis and accretion was increased compared with control animals but again less so than in the nonfasted animals. In contrast to nonfasted animals, neither hormone increased the fractional synthetic rate of skeletal muscle protein nor that of plasma albumin. These results indicate that a short but severe nutritional stress can significantly alter the fetal anabolic response to insulin even when both glucose and amino acid substrate supplies are restored. Therefore, adaptive responses characterized by insulin resistance begin in utero when the fetus is subjected to sufficient nutritional stress.
Shen
Weihua
W
Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Inidiana, USA.
Wisniowski
Paul
P
Denne
Scott C
SC
Boyle
David W
DW
Liechty
Edward A
EA
D000222:Adaptation, Physiological / Q000502:physiology; D000596:Amino Acids / Q000097:blood*; D045930:Anabolic Agents / Q000008:administration & dosage; D000818:Animals; D001798:Blood Proteins / Q000032:analysis*; D005215:Fasting / Q000502:physiology*; D005260:Female; D005333:Fetus / Q000187:drug effects* / Q000378:metabolism*; D007328:Insulin / Q000008:administration & dosage*; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage*; D008431:Maternal-Fetal Exchange / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy; D012756:Sheep; D014930:Women
D000596:Amino Acids; D045930:Anabolic Agents; D001798:Blood Proteins; D007328:Insulin; D007334:Insulin-Like Growth Factor I